Calif. Appeals Court Overturns Preemption Ruling in Risperdal Gynecomastia Cases
May 12, 2020
DOCUMENTS
- Opinion
LOS ANGELES — A California appellate court has reinstated the eligibility of thousands of Risperdal and Invega gynecomastia cases, finding the failure-to-warn claims are not preempted because there is clear evidence that the FDA would have allowed Janssen Pharmaceuticals Inc. to change the drug’s label via the Changes Being Effected process.
In a May 8 opinion, the California Court of Appeal, 2nd District, agreed with plaintiffs that when seeking approval for its antipsychotic drug Risperdal (risperidone), Janssen failed to submit evidence showing that boys taking the drug were at greater risk of developing enlargement of breast tissue.
Specifically, a data …
UPCOMING CONFERENCES
HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation Conference
January 10, 2025 - Long Beach, CA
The Westin Long Beach
HarrisMartin's New Jersey Asbestos Litigation Conference
February 27, 2025 - New Brunswick, NJ
Hyatt Regency New Brunswick